New study aims to predict which prostate cancer patients benefit from Lu-PSMA therapy

NCT ID NCT06600802

Recruiting now Knowledge-focused Sponsor: Centre Jean Perrin Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is looking for genetic clues in tumor tissue that could predict whether Lu-PSMA treatment will be effective for men with advanced, castration-resistant prostate cancer. About 120 men who have already tried other treatments will provide tumor samples for analysis. The goal is to find markers that help doctors choose the right treatment for each patient.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CASTRATION RESISTANT METASTATIC PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CASTRATION RESISTANT METASTATIC PROSTATE CANCER TREATED BY 177LUTETIUM-PSMA-617 (LU-PSMA)

Contacts and locations

Locations

CHU de Grenoble
NOT_YET_RECRUITING

La Tronche, 38700, France
Centre Jean PERRIN
RECRUITING

Clermont-Ferrand, 63011, France
Centre Paul STRAUSS
NOT_YET_RECRUITING

Strasbourg, 67091, France
Hospices Civiles de Lyon
NOT_YET_RECRUITING

Pierre-Bénite, 69310, France
Hôpital privé de la Loire
NOT_YET_RECRUITING

Saint-Etienne, 42100, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.